Holen Sie sich die Stockscreener-App
12.40
2.90%
-0.34
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
NTLA Reiterates by Citizens -- Price Target Maintained at $30 - GuruFocus
Intellia Therapeutics Stock Short Interest Rises to 40.35% - Quiver Quantitative
NTLA Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
H.C. Wainwright reiterates Intellia stock rating on FDA review progress - Investing.com
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com India
NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Canada
Citizens reiterates Intellia stock rating on HAE opportunity potential By Investing.com - Investing.com Nigeria
Intellia’s Lonvo-z Gains FDA Priority Review for HAE - TipRanks
Intellia Announces FDA Acceptance of BLA for Lonvo-z with PDUFA Date March 10, 2027 - TradingView
Intellia Therapeutics Obtains $400M Senior Secured Credit Facility (NASDAQ: NTLA) - Kalkine Media
Intellia’s one-shot CRISPR therapy gets March 2027 FDA decision date - AllSci
Intellia Therapeutics stock jumps on FDA priority review By Investing.com - Investing.com Nigeria
Intellia Therapeutics Says FDA Accepts Lonvo-z BLA for Hereditary Angioedema - marketscreener.com
NTLA Looks 4.8% Undervalued on GF Value™ Amid FDA Priority Review - GuruFocus
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform - Stocktwits
Why is Intellia Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Why is Intellia Therapeutics stock rallying today? - Investing.com
Intellia stock rises on FDA priority review (NTLA:NASDAQ) - Seeking Alpha
NTLA Looks 4.0% Undervalued on GF Value™ as FDA Advances Lonvo-z Review - GuruFocus
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z - Yahoo Finance
Intellia Therapeutics stock jumps on FDA priority review - Investing.com
If approved, a one-time treatment could be the world's first in-body gene-editing therapy for hereditary angioedema. - Stock Titan
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) - Intellia Therapeutics
FDA grants lonvo-z priority review - CRISPR Medicine News
symbol__ Stock Quote Price and Forecast - CNN
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates - Eastern Progress
Intellia Therapeutics, Inc. | NTLA Stock Price & Real-time Quotes - finance.biggo.com
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Intellia Locks In $400 Million OrbiMed Loan Tied to HAE Drug Milestones - finance.biggo.com
Intellia Therapeutics Stock Price Forecast. Should You Buy NTLA? - StockInvest.us
Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In - Yahoo Finance
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength? - Eastern Progress
Should Intellia’s Milestone-Linked OrbiMed Loan Reshape Funding Risk Perceptions For Intellia Therapeutics (NTLA) Investors? - Yahoo Finance
Intellia Therapeutics Secures Major Non-Dilutive Loan Financing - TipRanks
Intellia Therapeutics Secures Up to $400 Million Five-Year Secured Credit Facility From OrbiMed - TradingView
FDA decision could unlock more of Intellia (NASDAQ: NTLA) $400M loan - Stock Titan
41 new hires get Intellia stock awards that vest annually for 3 years - Stock Titan
Intellia secures USD 400m non-dilutive debt facility ahead of lonvo-z commercial launch - AllSci
Intellia Therapeutics, Inc. Secures Non-Dilutive Debt Facility With OrbiMed For Up To $400 Million - marketscreener.com
NTLA Looks 4.3% Undervalued on GF Value™ Amid Strategic $400M Lo - GuruFocus
Intellia Therapeutics Enters $400 Million OrbiMed Term Loan Facility - marketscreener.com
Intellia Therapeutics Secures Up to $400 Million OrbiMed Debt Facility - citybiz.co
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million - The Manila Times
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million - GlobeNewswire Inc.
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference - Intellia Therapeutics
Tracking Cathie Wood: Adding to Gene Editing Leader Intellia, Trimming Brera Holdings - Moomoo
Cathie Wood’s ARK buys Intellia stock, sells Brera holdings - Investing.com
Intellia Therapeutics, Inc. announced that it expects to receive $400 million in funding - marketscreener.com
Cathie Wood’s ARK sells Shopify stock, buys Intellia Therapeutics By Investing.com - Investing.com South Africa
Cathie Wood’s ARK sells Shopify stock, buys Intellia Therapeutics - Investing.com
Intellia Therapeutics (NTLA) CEO sells shares around $13 - Stock Titan
Intellia Therapeutics Inc (XTER:38I) Stock Price & 30 Year Financial Data - GuruFocus
Who's Buying or Selling Intellia Therapeutics Inc (XTER:38I) Stock Today? - GuruFocus
Intellia Therapeutics Inc Stock Baskets | XTER:38I - GuruFocus
Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
John M. Leonard to sell 22,675 Intellia (NASDAQ: NTLA) shares - Stock Titan
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.4%Time to Sell? - MarketBeat
Bank of America Corp DE Grows Stock Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 10.7%Here's What Happened - MarketBeat
Trending Industry Today: Intellia Therapeutics Leads Gains In Gene Editing Stocks - Moomoo
Will Narrowing Six‑Month Losses Shape Intellia Therapeutics' (NTLA) Gene‑Editing Investment Narrative? - Sahm
1.30%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):